


One in five with non-valvular A-fib receiving digoxin

September 30 2016



(HealthDay)—About one in five patients with non-valvular atrial

fibrillation (NVAf) receives digoxin, with the indication for use considered inappropriate in nearly 60 percent, according to a study published online Sept. 27 in the *Journal of Clinical Pharmacy and Therapeutics*.

Murat Bitekar, M.D., from Mugla Sitki Kocman University in Turkey, and colleagues analyzed data from 6,200 patients with NVAf from the Real-Life Multicentre Survey Evaluating Stroke Prevention Strategies in Turkey study to examine the prevalence, indications, and appropriateness of digoxin use.

The researchers found that 20.5 percent of patients used digoxin. Patients using digoxin were older, more likely to be female, and more frequently had comorbidities such as heart failure, diabetes, [coronary artery disease](#), and persistent/permanent AF. The indication for digoxin use was considered inappropriate in 59.8 percent of the 1,274 patients.

"Our findings show that nearly one-fifth of the patients with NVAf were on digoxin therapy and nearly 60 percent of these patients were receiving [digoxin](#) with inappropriate indications in a real-world setting," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: One in five with non-valvular A-fib receiving digoxin (2016, September 30) retrieved 20 March 2024 from <https://medicalxpress.com/news/2016-09-non-valvular-a-fib-digoxin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.